Evidence map›Paper›PMID 41081889›Full record

ArticleVirchows Archiv : an international journal of pathology2026

FOS gene fusions in osteosarcoma raise the hypothesis of malignant transformation of osteoblastoma.

Christophe Bontoux, Marie Csanyi-Bastien, Corinne Bouvier, Frédérique Larousserie, Hervé Sartelet, Marie-Paule Algros, Frédéric Bibeau, Sébastien Aubert, Gonzague de Pinieux, Marie Faruch-Bilfeld and 9 more

Abstract readMulticenter StudyCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Christophe BontouxDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France.
Marie Csanyi-BastienInstitute of Pathology, Centre de Biologie Pathologie, Lille University Hospital, Lille, 59000, France.
Corinne BouvierPathology Department, APHM Hopital La Timone, Aix-Marseille University, Marseille, France.
Frédérique LarousseriePathology Department, Hôpital Cochin, Paris, AP-HP, France.
Hervé SarteletDepartment of Pathology, Grenoble Alpes University Hospital, Grenoble, France.
Marie-Paule AlgrosDepartment of Pathology, CHRU Besançon, Besançon, 25000, France.
Frédéric BibeauDepartment of Pathology, CHRU Besançon, Besançon, 25000, France.
Sébastien AubertInstitute of Pathology, Centre de Biologie Pathologie, Lille University Hospital, Lille, 59000, France.
Gonzague de PinieuxDepartment of Pathology, Trousseau University Hospital, Tours, France.
Marie Faruch-BilfeldUniversity Hospital Centre Toulouse, Radiology Unit, Toulouse, France.
Natacha RousselOncoSarc, INSERM U1037, Cancer Research Center in Toulouse, Toulouse, 31000, France.
Sofia GalanouOncoSarc, INSERM U1037, Cancer Research Center in Toulouse, Toulouse, 31000, France.
Nathalie Van AckerDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France.
David GrandDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France.
Mélanie LarquierDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France.
Sophie PeriesCancer Biobank, Cancer University Institute of Toulouse-Oncopole, Toulouse, 31059, France.
Pierre BroussetDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France.
Solène EvrardDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France.
Anne Gomez-MascardDepartment of Pathology, Cancer University Institute of Toulouse-Oncopole, University Hospital of Toulouse, Irène Joliot-Curie, Toulouse, 1 Av, 31059, France. Gomez.anne@chu-toulouse.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is the most common malignant bone tumor among children and young adults. Distinguishing between osteoblastoma and osteosarcoma can be particularly challenging, especially in small tissue samples and for the osteoblastoma-like osteosarcoma subtype. Recent studies with conflicting results have suggested a potential malignant transformation process from osteoblastoma to osteosarcoma. This study aims to investigate the hypothesis of osteoblastoma evolving into osteosarcoma and to discuss its clinical implications. We conducted a retrospective multicentric case-series study, collecting clinical, radiological, histological, and follow-up data from osteosarcoma cases suspected to have originated from malignant transformation of osteoblastoma within the French ResOs network. Molecular analyses (fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS)) were performed. We included two cases (one female and one male), with a median age at osteosarcoma diagnosis of 42 and 73 years old, respectively. One patient had tumor located in the axial skeleton, and both cases exhibited features of osteoblastoma-like osteosarcoma. Notably, one of the patients had a documented history of osteoblastoma diagnosed sixteen years earlier. FISH analysis revealed FOS rearrangements in both osteosarcoma cases, with tumors presenting uncommon fusion transcripts (FOS::VGLL4 and FOS::COL5A2) identified through NGS. Both patients were alive at last follow-up. Our findings suggest that osteosarcoma can rarely present with FOS gene fusions and be associated with an indolent progression, challenging the specificity of such signatures for osteoblastoma diagnosis. This discovery also raises the hypothesis of malignant transformation from osteoblastoma to osteosarcoma and underscores the necessity for diligent monitoring of FOS-rearranged bone-forming tumors for optimal therapeutic management.

Indexed as

Biomarkers, TumorBone NeoplasmsCell Transformation, NeoplasticGene FusionOsteoblastomaOsteosarcomaProto-Oncogene Proteins c-fosAdultAgedFemaleHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedRetrospective StudiesBiomarkers, TumorFOS protein, humanProto-Oncogene Proteins c-fosFOSMalignant transformationNext-generation sequencingOsteoblastomaOsteosarcoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.